LXRX · Lexicon Pharmaceuticals Inc
United States · RS rating 26 · As of 2026-10-14
| Price | 1.60 USD |
|---|---|
| 1-day change | -0.6% |
| RS rating (overall / 1M / 3M / 12M) | 26 / 11 / 12 / 62 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 28 / 36 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | -61.3% |
| Distance from 52-week high | +39.4% |
| Market cap (USD) | $711.8M |